Charmacy Pharmaceutical Co., Ltd. provided earnings guidance for the ended 31 December 2021. For the period, the group is expected to report a net profit attributable to the shareholders of the parent company of approximately RMB 21.00 million to RMB 25.00 million for the Year, representing a decrease of approximately 38% to 48% as compared with that of the year ended 31 December 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.5 HKD | -1.16% |
|
-1.28% | -34.41% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.41% | 119M | |
-39.22% | 13.9B | |
-39.51% | 10.15B | |
-17.69% | 7.35B | |
-13.14% | 5.77B | |
-16.29% | 4.81B | |
-3.21% | 4.57B | |
+4.39% | 4.57B | |
+70.00% | 4.45B | |
-19.91% | 2.61B |
- Stock Market
- Equities
- 2289 Stock
- News Charmacy Pharmaceutical Co., Ltd.
- Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021